Skip to main content

News Releases

Menu
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
December 12, 2022
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 Download PDF format download (opens in new window)
October 27, 2022
Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat Download PDF format download (opens in new window)
October 17, 2022
Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress Download PDF format download (opens in new window)
October 3, 2022
TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations Download PDF format download (opens in new window)
September 21, 2022
Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement Download PDF format download (opens in new window)
September 13, 2022
Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer Download PDF format download (opens in new window)
September 11, 2022
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups Download PDF format download (opens in new window)
August 8, 2022
Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs Download PDF format download (opens in new window)
July 20, 2022
CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8 Download PDF format download (opens in new window)
June 14, 2022
Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting Download PDF format download (opens in new window)
June 6, 2022
Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status Download PDF format download (opens in new window)
May 5, 2022
Clovis Oncology to Present at the BofA Securities 2022 Healthcare Conference Download PDF format download (opens in new window)
May 4, 2022
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs Download PDF format download (opens in new window)
April 28, 2022
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting Download PDF format download (opens in new window)
April 20, 2022
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4 Download PDF format download (opens in new window)
April 8, 2022
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022 Download PDF format download (opens in new window)
March 31, 2022
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial Download PDF format download (opens in new window)
March 16, 2022
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286 Download PDF format download (opens in new window)
February 25, 2022
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting Download PDF format download (opens in new window)
February 23, 2022
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones Download PDF format download (opens in new window)
February 10, 2022
Clovis Oncology to Announce Fourth Quarter 2021 and Year End 2021 Financial Results and Host Webcast Conference Call Download PDF format download (opens in new window)
January 10, 2022
Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 Download PDF format download (opens in new window)